Wilms tumor 1 expression: addressing the 'elephant' in MDS

Clinical and Genomic Convergence of High-Risk CCUS and Lower-Risk Myelodysplastic Syndromes/Neoplasms.

Blood·2026

OPTI-AML: Prospective Comparison of 28 vs.14 days of Venetoclax Induction with Azacitidine in Older Adults with AML.

Blood·2026

Comprehensive analysis of prognostic factors in myelodysplastic syndromes with isolated deletion of chromosome 5q.

Blood advances·2026

NCCN Guidelines® Insights: Myeloproliferative Neoplasms, Version 2.2026.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA.

American journal of hematology·2026

Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database.

Blood cancer journal·2026

Efficacy and tolerability of venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukemia - real-world analysis of Polish adult leukemia study group.

Leukemia & lymphoma·2026

Prognostic significance of baseline liver enzyme patterns in chronic lymphocytic leukemia: a nationwide real-world cohort study.

Leukemia & lymphoma·2026

A phase II study of low dose melphalan with thiotepa and fludarabine as preparative regimen for alternative donor transplantation.

Leukemia & lymphoma·2026

Multimorbidity patterns and survival outcomes in older adults with multiple myeloma: findings from SEER-Medicare.

Leukemia & lymphoma·2026

Efficacy of imatinib maintenance after stem cell transplantation for Ph+/BCR::ABL1 positive ALL: long-term outcome of a randomized trial and impact of peritransplant minimal residual disease.

Leukemia & lymphoma·2026

Venetoclax and hypomethylating agents versus other therapies: an international, multicenter, retrospective cohort chart review study.

Leukemia & lymphoma·2026

RAVEN: Robust, generalizable, multi-resolution structural MRI upsampling using autoencoders.

Imaging neuroscience (Cambridge, Mass.)·2026

MA Dental Plan Enrollment And Generosity Increased, But Continuity Of Coverage Declined, 2010-25.

Health affairs (Project Hope)·2026

Aerobiology and Transmission of Mycobacterium tuberculosis.

Cold Spring Harbor perspectives in medicine·2026

Advancing the measurement of favorable selection in Medicare Advantage: evidence from encounter data.

Health affairs scholar·2026

MALAT1/miR-146a/COX-2 Expression Profile Six Months After Myocardial Infarction and Association of MALAT1 rs3200401 and miR-146a rs2910164 with Disease Susceptibility.

Biomedicines·2026

Evolution of MUC1 During Retrotransposon Expansion as a Potential Adaptation Exploited in Human Cancer.

International journal of molecular sciences·2026

Related Experiment Videos

Wilms tumor 1 expression: addressing the 'elephant' in MDS

Related Concept Videos

Clinical and Genomic Convergence of High-Risk CCUS and Lower-Risk Myelodysplastic Syndromes/Neoplasms.

OPTI-AML: Prospective Comparison of 28 vs.14 days of Venetoclax Induction with Azacitidine in Older Adults with AML.

Comprehensive analysis of prognostic factors in myelodysplastic syndromes with isolated deletion of chromosome 5q.

NCCN Guidelines® Insights: Myeloproliferative Neoplasms, Version 2.2026.

Signaling Mutations Negate the Favorable Impact of NPM1 Mutations in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With VEN/HMA.

Outcomes of patients with higher-risk myelodysplastic syndromes/neoplasms treated with hypomethylating agents + venetoclax-an analysis from the International Consortium for MDS (icMDS) VALIDATE database.

Efficacy and tolerability of venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukemia - real-world analysis of Polish adult leukemia study group.

Prognostic significance of baseline liver enzyme patterns in chronic lymphocytic leukemia: a nationwide real-world cohort study.

A phase II study of low dose melphalan with thiotepa and fludarabine as preparative regimen for alternative donor transplantation.

Multimorbidity patterns and survival outcomes in older adults with multiple myeloma: findings from SEER-Medicare.

Efficacy of imatinib maintenance after stem cell transplantation for Ph+/BCR::ABL1 positive ALL: long-term outcome of a randomized trial and impact of peritransplant minimal residual disease.

Venetoclax and hypomethylating agents versus other therapies: an international, multicenter, retrospective cohort chart review study.

RAVEN: Robust, generalizable, multi-resolution structural MRI upsampling using autoencoders.

MA Dental Plan Enrollment And Generosity Increased, But Continuity Of Coverage Declined, 2010-25.

Aerobiology and Transmission of Mycobacterium tuberculosis.

Advancing the measurement of favorable selection in Medicare Advantage: evidence from encounter data.

MALAT1/miR-146a/COX-2 Expression Profile Six Months After Myocardial Infarction and Association of MALAT1 rs3200401 and miR-146a rs2910164 with Disease Susceptibility.

Evolution of MUC1 During Retrotransposon Expansion as a Potential Adaptation Exploited in Human Cancer.

Related Experiment Videos

Wilms tumor 1 expression: addressing the 'elephant' in MDS

Related Concept Videos

Related Articles